Sarepta Therapeutics Stock
Price
Target price
€139.95
€139.95
-1.100%
-1.55
-1.100%
€185.00
22:26 / Tradegate
WKN: A1J1BH / Symbol: AVII / Name: Sarepta / Stock / Biotechnology & Medical Research / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Sarepta Therapeutics Stock
A loss of -1.100% shows a downward development for Sarepta Therapeutics.
Sarepta Therapeutics is currently one of the favorites of our community with 9 Buy predictions and no Sell predictions.
With a target price of 185 € there is a positive potential of 32.19% for Sarepta Therapeutics compared to the current price of 139.95 €.
So far the community has only identified positive things for Sarepta Therapeutics stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Sarepta Therapeutics in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
S********** s********
Cons
?
B****
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Sarepta Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Sarepta Therapeutics | -1.100% | -4.202% | 28.442% | 35.979% | 59.754% | 114.232% | 4.735% |
| Exact Sciences | 3.000% | -3.730% | 0.175% | -53.320% | -41.631% | -61.334% | -62.293% |
| Incyte Corp. | -1.280% | -6.978% | -0.929% | -6.193% | -6.027% | -24.304% | -29.980% |
| Regeneron Pharmaceuticals Inc. | 0.490% | -3.625% | 3.704% | 43.721% | 18.671% | 92.358% | 234.299% |
Comments
News
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?
When a company obtains positive news from the Food and Drug Administration (FDA), such as the approval of a treatment or a label expansion, it can mark a milestone for the business and lead to
1 Soaring Growth Stock to Buy and Hold for 10 Years
Most investors know the phrase "buy low, sell high." It's a fine piece of investing wisdom, but it isn't as straightforward as it seems. Even a company whose shares are performing well can be
Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.
When one player stumbles in a high-stakes competition, it's often to the glee of the other contenders. In mid-June, Pfizer's (NYSE: PFE) gene-therapy candidate to treat Duchenne muscular dystrophy